A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Gunagratinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors InnoCare Pharma
- 05 Feb 2024 Planned number of patients changed from 64 to 70.
- 08 Feb 2021 New trial record